According to published studies\u00b9, individuals with a high genetic risk (top 20% of the Polygenic Risk Score \u2013 PRS) are 91% more likely to develop coronary artery disease compared to those with low PRS (bottom 20%). However, even individuals at high genetic risk can reduce their risk of coronary artery disease by up to 50% through healthy lifestyle choices such as quitting smoking, engaging in physical activity, maintaining a healthy weight, and following a tailored diet.<\/p>\n
The test combines 31 genetic variants with GENOSOPHY\u00ae\u2019s award-winning algorithm, ensuring high reliability in assessing genetic risk.<\/p>\n
This test estimates the relative risk of coronary artery disease in the general population (excluding familial genetic risk). It is recommended for:<\/p>\n
Individuals with intermediate risk for cardiovascular disease, where PRS assessment may significantly improve clinical decision-making accuracy.<\/p>\n<\/li>\n
Younger individuals who wish to assess their long-term risk for cardiovascular conditions.<\/p>\n<\/li>\n<\/ul>\n
Diagnosis:<\/strong> More accurate identification of individuals with increased genetic risk for coronary artery disease who may require closer monitoring.<\/p>\n<\/li>\n Prognosis:<\/strong> Reliable prediction of the risk of cardiac events, contributing to personalized preventive strategies.<\/p>\n<\/li>\n Management:<\/strong> Design of personalized preventive interventions in diet and lifestyle based on genetic risk.<\/p>\n<\/li>\n<\/ul>\n Genetic Risk Assessment for Dyslipidemias<\/strong><\/p>\n According to published studies\u00b9\u00b2, individuals with a high genetic score have up to a 45% higher risk of lipid disorders. Specifically, the relative risk increases are:<\/p>\n Total Cholesterol (TC): 13% higher<\/p>\n<\/li>\n LDL Cholesterol: 18% higher<\/p>\n<\/li>\n Triglycerides (TAG): 39% higher<\/p>\n<\/li>\n TAG:HDL Ratio: 45% higher<\/p>\n<\/li>\n<\/ul>\n Even for individuals at high genetic risk, personalized nutrition can reduce the risk of dyslipidemia and improve their lipid profile.<\/p>\n The GENOSOPHY genetic test assesses the risk of lipid disorders using 2 Polygenic Risk Scores (PRS) and analyzes 14 genetic variants through its award-winning algorithm.<\/p>\n The test estimates the relative risk for lipid disorders in the general population and is recommended for:<\/p>\n Younger individuals who wish to evaluate their risk of elevated LDL cholesterol and triglycerides or low HDL cholesterol levels.<\/p>\n<\/li>\n Individuals interested in adjusting their diet and lifestyle based on their genetic profile to reduce the risk of dyslipidemia.<\/p>\n<\/li>\n<\/ul>\n Diagnosis:<\/strong> Identification of individuals with increased genetic risk for dyslipidemia.<\/p>\n<\/li>\n Prognosis:<\/strong> Reliable risk prediction of elevated lipid levels, supporting personalized preventive strategies.<\/p>\n<\/li>\n Management:<\/strong><\/p>\n Personalized nutritional and lifestyle interventions to regulate blood lipid levels.<\/p>\n<\/li>\n Selection of preventive strategies, especially for those with high genetic risk, following international clinical guidelines.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n According to published studies (Table 1), individuals carrying pathogenic variants are up to 7.5 times more likely to develop thrombosis. In carriers of multiple variants, the risk is even higher.<\/p>\n GENOSOPHY’s genetic test assesses thrombosis risk by analyzing 11 variants with its award-winning algorithm, enabling personalized interventions to lower the risk or improve disease management.<\/p>\n This test estimates the relative risk of thrombosis in the general population and is recommended for:<\/p>\n Individuals with a family history of thromboembolic events<\/p>\n<\/li>\n Women with a history of recurrent pregnancy loss<\/p>\n<\/li>\n Individuals looking to tailor their lifestyle and treatment approach based on their genetic profile<\/p>\n<\/li>\n<\/ul>\n Diagnosis:<\/strong><\/p>\n Identification of individuals with increased genetic risk for thrombosis, allowing timely intervention and personalized medical monitoring<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Prognosis:<\/strong><\/p>\n Reliable risk prediction for venous and arterial thrombosis, supporting personalized preventive strategies<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Management:<\/strong><\/p>\n Design of personalized preventive strategies including tailored diet, anticoagulant use, and individualized monitoring<\/p>\n<\/li>\n Selection of prevention strategies based on international clinical guidelines, especially for high-risk individuals<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n Collection of a saliva sample<\/p>\n<\/li>\n Analysis of 56 genetic variants and calculation of relative risks using GENOSOPHY\u00ae\u2019s award-winning algorithm<\/p>\n<\/li>\n Delivery of results in 5\u20136 weeks<\/p>\n<\/li>\n<\/ol>\n Based on genetic test results and each individual\u2019s genetic profile, GENOSOPHY\u00ae offers additional services to maximize the effectiveness of preventive interventions:<\/p>\n Genetic counseling<\/p>\n<\/li>\n Personalized diet plans based on genetic profile<\/p>\n<\/li>\n Nutritional consulting<\/p>\n<\/li>\n<\/ul>\n Khera et al., N Engl J Med 2016;375:2349-2358 \/ DOI: 10.1056\/NEJMoa160508<\/p>\n<\/li>\n Wuni et al., Br J Nutr 2024;132(5):575-589 \/ DOI: 10.1017\/S0007114524001594<\/p>\n<\/li>\n Park et al., Nutrients 2020;12(12):3840 \/ DOI: 10.3390\/nu12123840<\/p>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":" A) Cardiovascular Diseases Genetic Risk Assessment for Coronary Artery Disease According to published studies\u00b9, individuals with a high genetic risk (top 20% of the Polygenic Risk Score \u2013 PRS) are 91% more likely to develop coronary artery disease compared to those with low PRS (bottom 20%). However, even individuals at high genetic risk can reduce […]<\/p>\n","protected":false},"featured_media":2461,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[75],"product_tag":[],"class_list":{"0":"post-2695","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-cardio-ipersies-gia-epaggelmaties-en","8":"first","9":"instock","10":"taxable","11":"shipping-taxable","12":"product-type-simple"},"acf":[],"_links":{"self":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product\/2695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media\/2461"}],"wp:attachment":[{"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/media?parent=2695"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_brand?post=2695"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_cat?post=2695"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/genosophy.gr\/en\/wp-json\/wp\/v2\/product_tag?post=2695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}B) Dyslipidemia<\/h3>\n
\n
Conditions covered by the test<\/h4>\n
\n
Clinical Benefits of GENOSOPHY\u00ae\u2019s PRS<\/h4>\n
\n
\n
C) Genetic Testing for Thrombosis<\/h3>\n
Genetic Risk Assessment for Thrombosis<\/h4>\n
Conditions covered by the test<\/h4>\n
\n
Clinical Benefits of GENOSOPHY\u00ae\u2019s PRS<\/h4>\n
\n
\n
\n
\n
Genes analyzed:<\/h3>\n
\n\n
\n \nGene<\/th>\n Polymorphism<\/th>\n Effect<\/th>\n Association<\/th>\n References<\/th>\n<\/tr>\n<\/thead>\n \n MTHFR<\/td>\n C677T<\/td>\n Increased risk of thrombosis and pregnancy loss<\/td>\n Thrombosis, Pregnancy Loss<\/td>\n PMID: 29212064, 9669991<\/td>\n<\/tr>\n \n MTHFR<\/td>\n A1298C<\/td>\n Increased risk of thrombosis and pregnancy loss<\/td>\n Thrombosis, Pregnancy Loss<\/td>\n PMID: 29212064, 9669991<\/td>\n<\/tr>\n \n Factor II<\/td>\n G20210A<\/td>\n 7.5x higher risk of thrombosis during pregnancy<\/td>\n Thrombosis, Pregnancy Loss<\/td>\n PMID: 10666427<\/td>\n<\/tr>\n \n Factor V<\/td>\n Leiden G1691A<\/td>\n 3x risk (heterozygous), 18x (homozygous)<\/td>\n Thrombosis, Pregnancy Loss<\/td>\n PMID: 14996674<\/td>\n<\/tr>\n \n Factor XIII<\/td>\n V34L<\/td>\n Protective effect against thrombosis<\/td>\n Thrombosis, Pregnancy Loss<\/td>\n PMID: 16740590, 16938111<\/td>\n<\/tr>\n \n PAI-1<\/td>\n 4G\/4G<\/td>\n Increased plasminogen levels, increased risk<\/td>\n Thrombosis, Pregnancy Loss<\/td>\n PMID: 11091191, 25250948<\/td>\n<\/tr>\n \n FGB<\/td>\n -455G>A<\/td>\n Elevated fibrinogen levels<\/td>\n Stroke, Heart Attack, Pregnancy Loss<\/td>\n PMID: 3626001, 23926530<\/td>\n<\/tr>\n \n ApoE<\/td>\n E4<\/td>\n Associated with venous thrombosis in women<\/td>\n Thrombosis, Pregnancy Loss<\/td>\n PMID: 22006422, 24221911<\/td>\n<\/tr>\n \n ACE<\/td>\n DEL\/DEL<\/td>\n Increased risk of thrombosis and pregnancy loss<\/td>\n Thrombosis, Pregnancy Loss<\/td>\n PMID: 12864773, 11085286<\/td>\n<\/tr>\n \n GPIa<\/td>\n C807T<\/td>\n Increased platelet aggregation<\/td>\n Thrombosis, Stroke, Heart Attack<\/td>\n PMID: 16214444, 11703818<\/td>\n<\/tr>\n \n GPIIIa<\/td>\n PIA2<\/td>\n Increased platelet aggregation, reduced response to antithrombotics<\/td>\n Thrombosis, Heart Attack<\/td>\n PMID: 8598867, 11723016<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n Test Process<\/h3>\n
\n
Additional Services<\/h3>\n
\n
Selected References:<\/h3>\n
\n